Benzinga

Benzinga

Benzinga

samedi, août 29

Structure Therapeutics Inc

GPCRNASDAQ
Trade with Public
Trade with Public
$47.37
-1.85-3.76%
À la clôture: Aug 28, 5:00 PM EST
$47.37
N/A
Après les heures: 4:00 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Structure Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Structure Therapeutics (GPCR).

Price Target Range — 13 Quarters

Analyst Consensus — 16 Analysts

3S.Buy
13Buy
Consensus RatingBuy# Analysts16Avg. Consensus PT$98Upside to Avg. PT+107.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 7, 2026CitigroupSamantha SemenkowPT CutBuy$100→$97
Aug 7, 2026CitizensJonathan WollebenPT CutMarket Outperform$113→$110
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citigroup Maintains Buy on Structure Therapeutics, Lowers Price Target to $97

Citigroup analyst Samantha Semenkow maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and lowers the price target from $100 to $97.
Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $110

Citizens analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and lowers the price target from $113 to $110.
Benzinga Newsdesk

Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed outlook on top names. See full list of rating changes on analyst ratings page: CHEF, NAVN, INTC, HOOD, GPCR, OTLK, ORCL.
Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $70

HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and lowers the price target from $100 to $70.
Benzinga Newsdesk

PRO
Canaccord Genuity Initiates Coverage On Structure Therapeutics with Buy Rating, Announces Price Target of $101

Canaccord Genuity analyst Edward Nash initiates coverage on Structure Therapeutics (NASDAQ:GPCR) with a Buy rating and announces Price Target of $101.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $100

HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and lowers the price target from $114 to $100.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved